Serum lipids and endometrial cancer risk: Results from the HUNT-II study

International Journal of Cancer

Volumn 124, Issue 12, 2009, Pages 2938-2941

  Lindemann, Kristina ^a   Vatten, Lars J ^b,c   Ellstrøm Engh, Marie ^a   Eskild, Anne ^a,d  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Blood lipids; Endometrial cancer; Epidemiology; Obesity

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; LIPID;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CANCER REGISTRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NORWAY; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENDOMETRIUM TUMOR; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 65649083344     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24285     Document Type: Article

References (30)

1. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;19:421-430 (Pubitemid 32049639)
2. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 2008;98:1582-1585 (Pubitemid 351652323)
3. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-1543 (Pubitemid 36020003)
4. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057-2062
5. Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O, Labate AM. Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. Metabolism 1997;46:5-9. (Pubitemid 27052016)
6. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, Trichopoulos D. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab 2002;46:147-151 (Pubitemid 34920698)
7. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La VC. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-1163 (Pubitemid 38368405)
8. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res 2006;55:233-244 (Pubitemid 43911041)
9. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990;31:1149-1172 (Pubitemid 20224714)
10. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjonneland A, Olsen A, Overvad K, Jakobsen MU, Chajes V, Clavel-Chapelon F, Boutron-Ruault MC, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14:755-767 (Pubitemid 350074064)
11. Swanson CA, Potischman N, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Hoover RN, Brinton LA. Endometrial cancer risk in relation to serum lipids and lipoprotein levels. Cancer Epidemiol Biomarkers Prev 1994;3:575-581
12. Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 1991;2:253-261
13. Romundstad S, Holmen J, Hallan H, Kvenild K, Kruger O, Midthjell K. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population. The Nord-Trondelag. Health Study (HUNT, 1995-1997), Norway. J Intern Med 2002;252:164-172
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Shumak SL, Campbell NR. Intraindividual variation in lipid and lipoprotein levels. CMAJ 1993;149:843-844 (Pubitemid 23345895)
16. Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB, Dawber TR. Cancer incidence by levels of cholesterol. JAMA 1981;245:247-252 (Pubitemid 11210650)
17. Kark JD, Smith AH, Hames CG. The relationship of serum cholesterol to the incidence of cancer in Evans County. Georgia. J Chronic Dis 1980;33:311-332 (Pubitemid 10083771)
18. Wallace RB, Rost C, Burmeister LF, Pomrehn PR. Cancer incidence in humans: relationship to plasma lipids and relative weight. J Natl Cancer Inst 1982;68:915-918 (Pubitemid 12040914)
19. Goodman MT, Hankin JH, Wilkens LR, Lyu LC, McDuffie K, Liu LQ, Kolonel LN. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res 1997;57:5077-5085 (Pubitemid 27498123)
20. Sattler AM, Soufi M, Maisch B, Schaefer JR. Lipids and lipoproteins in women. Herz 2005;30:368-374 (Pubitemid 41238954)
21. Haffner SM, Valdez RA. Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. Am J Med 1995;98:40S-47S.
22. Gil-Campos M, Canete R, Gil A. Hormones regulating lipid metabolism and plasma lipids in childhood obesity. Int J Obes Relat Metab Disord 2004;28 (Suppl 3):S75-S80. (Pubitemid 39564322)
23. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001;294:1866-1870 (Pubitemid 33101573)
24. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-1234 (Pubitemid 2102252)
25. Roberts-Thomson SJ. Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment. Immunol Cell Biol 2000;78:436-441 (Pubitemid 30655570)
26. Tachibana K, Yamasaki D, Ishimoto K, Doi T. The role of PPARs in cancer. PPAR Res 2008;2008:102737. (Pubitemid 352000629)
27. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245 (Pubitemid 17147964)
28. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418
29. Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006;5:13.
30. Ota K, Ito K, Suzuki T, Saito S, Tamura M, Hayashi S, Okamura K, Sasano H, Yaegashi N. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res 2006;12:4200-4208